All In Biotech

Drug Trial Radar · NCT05219500

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

Dec 16, 2021

Primary completion

May 30, 2025

Study completion Jul 31, 2026

Sponsor

Lead sponsor
Fusion Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Feb 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The treatment regimen will consist of 4 doses of FPI-2265

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

  • FPI-2265Drug

    Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of FPI-2265 on prostate-specific antigen (PSA) in participants with mCRPC.Time frame: From start of treatment until 12 weeks after the first treatment.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • XCancer Omaha/Urology Cancer Center

    Omaha, Nebraska

  • Excel Diagnostics and Nuclear Oncology Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.